CorMedix Inc. (NASDAQ: CRMD) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
7.79
-0.03-0.38%
TA
Loading chart...
Snapshot
| Index | - | P/E | 3.66 | EPS (ttm) | 2.13 | Insider Own | 12.91% | Shs Outstand | 78.45M | Perf Week | -2.14% |
| Market Cap | 611.14M | Forward P/E | 129.83 | EPS next Y | 0.06 | Insider Trans | 0.00% | Shs Float | 66.53M | Perf Month | -4.65% |
| Enterprise Value | 499.14M | PEG | 0.13 | EPS next Q | -0.10 | Inst Own | - | Short Float | 24.10% | Perf Quarter | -10.15% |
| Income | 188.00M | P/S | 1.32 | EPS this Y | -77.09% | Inst Trans | - | Short Ratio | 12.33 | Perf Half Y | 22.29% |
| Sales | 462.00M | P/B | 1.33 | EPS next Y | -87.70% | ROA | 20.70% | Short Interest | 16.03M | Perf YTD | -33.02% |
| Book/sh | 5.88 | P/C | 2.38 | EPS next 5Y | 28.24% | ROE | 44.64% | 52W High | 13.02 -40.17% | Perf Year | -32.79% |
| Cash/sh | 3.28 | P/FCF | 2.44 | EPS past 3/5Y | - | ROIC | 27.87% | 52W Low | 6.13 27.08% | Perf 3Y | 95.24% |
| Dividend Est. | - | EV/EBITDA | 2.00 | Sales past 3/5Y | - | Gross Margin | 82.78% | Volatility | 2.54% 3.14% | Perf 5Y | 66.10% |
| Dividend TTM | - | EV/Sales | 1.08 | EPS Y/Y TTM | 810.00% | Oper. Margin | 46.95% | ATR (14) | 0.29 | Perf 10Y | -10.97% |
| Dividend Ex-Date | - | Quick Ratio | 2.36 | Sales Y/Y TTM | 974.42% | Profit Margin | 40.49% | RSI (14) | 43.41 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.56 | EPS Q/Q | 3.57% | SMA20 | -4.87% | Beta | 1.40 | Target Price | 14.00 |
| Payout | 0.00% | Debt/Eq | 0.37 | Sales Q/Q | 155.00% | SMA50 | -2.37% | Rel Volume | 0.55 | Prev Close | 7.82 |
| Employees | 191 | LT Debt/Eq | 0.37 | Earnings | Nov 11 | SMA200 | -4.78% | Avg Volume | 1.23M | Price | 7.79 |
| IPO Date | May 13, 2010 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 21.85% 6.13% | Net Debt/EBITDA | -0.45 | Volume | 684,659 | Change | -0.38% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Apr-28-26 | Reiterated | RBC Capital | Outperform | $13 → $14 |
| Mar-06-26 | Reiterated | Leerink Partners | $13 | |
| Jan-23-26 | Reiterated | HC Wainwright & Co. | Buy | $17 → $13 |
| Jan-21-26 | Reiterated | RBC Capital | Outperform | $22 → $13 |
| Jan-08-26 | Reiterated | Truist Financial | Buy | $20 → $16 |
| Oct-21-25 | Reiterated | RBC Capital | Outperform | $9.00 → $22 |
| Oct-20-25 | Upgrade | D. Boral Capital | Hold → Buy | |
| Aug-08-25 | Reiterated | HC Wainwright & Co. | Buy | $17 |
| Jun-30-25 | Downgrade | D. Boral Capital | Buy → Hold | |
| Mar-13-24 | Reiterated | RBC Capital | Outperform | $9.00 |
Latest News· Times ET
Sep-07-26
06:55AM
Sep-01-26
Sep-01-2604:30AM
Aug-31-26
Aug-20-26
Aug-20-2606:56AM
Aug-18-26
Aug-14-26
Aug-13-26
07:07AM
CorMedix Q2 Earnings Call Highlightsmarketbeat.com
06:56AM
CorMedix Stock Jumps on Strong DefenCath Salesbenzinga.com
05:45AM
03:30AM
Aug-07-26
Aug-07-2612:24PM
Jul-29-26
Jul-29-2604:30AM
Company
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 462 | 312 | 43 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 79 | 36 | 3 | — | — | — | — | — | — | |
| Gross Profit | 382 | 276 | 40 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 139 | 30 | 59 | — | — | — | — | — | — | |
| Research and Development | 28 | 19 | 4 | — | — | — | — | — | — | |
| Other Operating Expense | -2 | 77 | 0 | — | — | — | — | — | — | |
| Operating Income | 217 | 150 | -22 | — | — | — | — | — | — | |
| Interest Expense | 3 | 3 | 0 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -11 | 3 | 3 | — | — | — | — | — | — | |
| Net Income Before Taxes | 204 | 150 | -19 | — | — | — | — | — | — | |
| Income Taxes | 16 | -13 | -1 | — | — | — | — | — | — | |
| Consolidated Net Income | 188 | 163 | -18 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 188 | 163 | -18 | — | — | — | — | — | — | |
| Net Income | 188 | 163 | -18 | — | — | — | — | — | — | |
| EPS (Recurring) | 2.41 | 2.25 | -0.30 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 2.41 | 2.25 | -0.30 | — | — | — | — | — | — | |
| EPS (Diluted) | 2.13 | 2.04 | -0.30 | — | — | — | — | — | — | |
| EBITDA | 249 | 168 | -19 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 3.66 | 5.70 | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 1.32 | 2.68 | 11.11 | — | — | — | — | — | — | |
| Gross Margin | 82.68 | 88.46 | 93.02 | — | — | — | — | — | — | |
| Operating Margin | 46.97 | 48.08 | -51.16 | — | — | — | — | — | — | |
| Net Margin | 40.69 | 52.24 | -41.86 | — | — | — | — | — | — | |
| Shares Outstanding | 78 | 72 | 59 | — | — | — | — | — | — | |
| Market Capitalization | 608 | 837 | 478 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Dillione Janet | Director | Jan 21 '26 | Sale | 6.88 | 10,000 | 68,800 | 38,473 | Jan 22 |
| Todisco Joseph | Chief Executive Officer | Jan 16 '26 | Option Exercise | 3.38 | 29,585 | 99,997 | 521,664 | Jan 20 |
| Lefkowitz Steven W | Director | Jan 12 '26 | Option Exercise | 5.63 | 15,000 | 84,450 | 95,498 | Jan 14 |
| DUNTON ALAN W | Director | Dec 30 '25 | Option Exercise | 4.03 | 20,000 | 80,600 | 60,250 | Jan 02 |
| DUNTON ALAN W | Director | Dec 30 '25 | Sale | 13.00 | 20,000 | 260,000 | 40,250 | Jan 02 |
| Todisco Joseph | Chief Executive Officer | Dec 18 '25 | Option Exercise | 4.43 | 30,000 | 132,900 | 539,496 | Dec 19 |
| Todisco Joseph | Chief Executive Officer | Dec 18 '25 | Sale | 12.00 | 30,000 | 360,000 | 509,496 | Dec 19 |
| Dillione Janet | Director | Dec 09 '25 | Option Exercise | 7.82 | 34,000 | 265,900 | 82,473 | Dec 11 |
| Dillione Janet | Director | Dec 09 '25 | Sale | 12.00 | 34,000 | 408,000 | 48,473 | Dec 11 |
| Lefkowitz Steven W | Director | Dec 09 '25 | Sale | 11.88 | 40,000 | 475,200 | 80,498 | Dec 10 |
| Dillione Janet | Director | Dec 02 '25 | Option Exercise | 3.96 | 46,657 | 184,802 | 95,130 | Dec 04 |
| Dillione Janet | Director | Dec 02 '25 | Sale | 10.00 | 46,657 | 466,570 | 48,473 | Dec 04 |
| Dillione Janet | Director | Nov 24 '25 | Option Exercise | 3.64 | 26,343 | 95,948 | 74,816 | Nov 26 |
| Dillione Janet | Director | Nov 24 '25 | Sale | 9.93 | 26,343 | 261,586 | 48,473 | Nov 26 |
| Dillione Janet | Director | Nov 14 '25 | Sale | 11.42 | 30,000 | 342,600 | 48,473 | Nov 18 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.